J&J Jumps On RNA-Based Small Molecules Train In Pact With Remix
Executive Summary
Deal Snapshot: The deal, with an upfront payment of $45m, is the latest of several involving large biopharma companies and smaller firms focused on small molecule drugs based on RNA biology.
You may also be interested in...
Remix Teams Up With Second Big Pharma With Roche Deal For RNA Technology
The news comes just under two years after Remix signed a partnership with J&J, and the biotech announced the same-day closing of a $60m financing to develop its lead product candidate.
The Busiest Dealmakers Of 2022
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
Sanofi Continues Hunt For External Innovation With Skyhawk Deal
Deal Snapshot: A lot of the French drug maker’s interest has focused on biologics, but the Skyhawk deal shows it has maintained a keen interest in innovative small molecules as well.